Candel Therapeutics Inc (CADL)
11.56
-1.14
(-8.98%)
USD |
NASDAQ |
May 17, 16:00
11.51
-0.05
(-0.43%)
After-Hours: 20:00
Candel Therapeutics SG&A Expense (Quarterly): 3.80M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.80M |
| December 31, 2023 | 3.06M |
| September 30, 2023 | 3.016M |
| June 30, 2023 | 3.645M |
| March 31, 2023 | 4.164M |
| December 31, 2022 | 3.16M |
| September 30, 2022 | 3.536M |
| June 30, 2022 | 3.762M |
| March 31, 2022 | 3.60M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.917M |
| September 30, 2021 | 2.795M |
| June 30, 2021 | 2.04M |
| March 31, 2021 | 1.935M |
| December 31, 2020 | 2.622M |
| September 30, 2020 | 0.967M |
| June 30, 2020 | 0.855M |
| March 31, 2020 | 0.728M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.728M
Minimum
Mar 2020
4.164M
Maximum
Mar 2023
2.800M
Average
3.06M
Median
Dec 2023
SG&A Expense (Quarterly) Benchmarks
| Allurion Technologies Inc | 12.53M |
| AngioDynamics Inc | 35.98M |
| Eliem Therapeutics Inc | 1.914M |
| Macrogenics Inc | 14.71M |
| GlycoMimetics Inc | 5.09M |